HUTCHISON CHINA/S (NASDAQ:HCM) Receives Consensus Rating of “Buy” from Brokerages

HUTCHISON CHINA/S (NASDAQ:HCM) has earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $25.41.

Several equities research analysts recently issued reports on HCM shares. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. BidaskClub downgraded Westport Fuel Systems from a “buy” rating to a “hold” rating in a research note on Friday, July 19th. Finally, Macquarie started coverage on Baozun in a research note on Friday, July 5th. They issued a “buy” rating and a $60.00 price objective for the company.

HUTCHISON CHINA/S stock traded down $0.44 during mid-day trading on Tuesday, hitting $20.22. The company’s stock had a trading volume of 4,780 shares, compared to its average volume of 479,359. The stock’s 50 day moving average is $23.86. The firm has a market cap of $2.76 billion, a P/E ratio of -36.32 and a beta of 0.71. The company has a current ratio of 4.33, a quick ratio of 4.19 and a debt-to-equity ratio of 0.06. HUTCHISON CHINA/S has a 52-week low of $19.37 and a 52-week high of $39.68.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of HUTCHISON CHINA/S during the 4th quarter valued at about $72,560,000. BNP Paribas Arbitrage SA increased its holdings in shares of HUTCHISON CHINA/S by 440.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,067,394 shares of the company’s stock valued at $63,221,000 after acquiring an additional 1,684,645 shares during the last quarter. Segantii Capital Management Ltd acquired a new position in shares of HUTCHISON CHINA/S during the 2nd quarter valued at about $19,806,000. Northern Trust Corp acquired a new position in shares of HUTCHISON CHINA/S during the 4th quarter valued at about $5,064,000. Finally, Bank of America Corp DE increased its holdings in shares of HUTCHISON CHINA/S by 4,660.7% during the 4th quarter. Bank of America Corp DE now owns 193,759 shares of the company’s stock valued at $4,474,000 after acquiring an additional 189,689 shares during the last quarter. 21.70% of the stock is owned by hedge funds and other institutional investors.

About HUTCHISON CHINA/S

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.

Featured Article: What is Compound Interest?

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.